Medivir presents the first clinical data with fostrox + Lenvima at the ASCO GI scientific congress, showing further improved clinical benefit vs previous interim updates from the ongoing phase Ib/IIa study in advanced hepatocellular carcinoma. According to the company, the data supports the planning for a pivotal phase IIb study in 2024. BioStock reached out to Pia Baumann, Medivir's CMO, to learn more about the new data.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.91 SEK | -1.36% | -3.00% | +2.11% |
May. 07 | Medivir Aktiebolag Approves Board Appointments | CI |
Apr. 30 | Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.11% | 30.48M | |
+3.93% | 111B | |
+11.38% | 105B | |
-12.84% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+2.41% | 13.7B | |
+35.95% | 12.45B |
- Stock Market
- Equities
- MVIR B Stock
- News Medivir AB
- Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress